Table 3.
Concentrations and percentage changes of differentially expressed cytokines.
|
Baseline (n = 31) |
Evolocumab (n = 31) |
% Change from baseline | P -value | |
|---|---|---|---|---|
| Pro-inflammatory cytokines | ||||
| IL-1β (pg/ml) | 0.72 [0.50, 1.14] | 0.47 [0.35, 0.53] | −37.7% (−49.2 to −14.6%) |
<0.0001 |
| IL-6 (pg/ml) | 2.12 [0.68, 4.51] | 1.11 [0.29, 3.63] | −60.5% (−76.5 to −15.9%) |
0.0309 |
| MCP-1 (pg/ml) | 9.20 [6.22, 12.19] | 8.07 [6.79, 9.20] | −15.9% (−32.8 to 13.8%) |
0.0408 |
| Anti-inflammatory cytokines | ||||
| IL-13 (pg/ml) | 1.72 [0.79, 2.83] | 0.61 [0.43, 0.96] | −57.6% (−75.5 to −41.5%) |
<0.0001 |
| IL-4 (pg/ml) | 2.88 [2.13, 3.43] | 2.59 [2.22, 3.14] | −10.1% (−19.6 to −2.2%) |
0.0388 |
| Growth factors | ||||
| GM-CSF (pg/ml) | 0.53 [0.46, 0.85] | 0.46 [0.34, 0.53] | −26.1% (−30.6 to −13.2%) |
0.0013 |
| VEGF (pg/ml) | 0.10 [0.06, 0.18] | 0.06 [0.04, 0.10] | −40.0% (−60.0 to 0.0%) |
0.0198 |
Data expressed as median [interquartile range] for cytokine concentrations and as median difference with 95% confidential interval for % change from baseline, respectively. Differences were tested using Wilcoxon matched-pairs signed rank test.